Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators

Abstract excerpt

The formation of pathological anti-FVIII antibodies, referred to as “inhibitors” affects up to 1/3 of severe Hemophilia A (HA) patients. “Immune Tolerance Induction” (ITI), enables ~2/3 of treated patients to achieve peripheral tolerance to FVIII. Inhibitor formation is a classical T-cell dependent adaptive immune response. As such, it requires help from the innate immune system. However, the roles of innate...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related gene regulation
• Share to Hemophilia Treatment and Research
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment